The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 05, 2005
Filed:
May. 10, 2002
James Knobelsdorf, Knoblesville, IN (US);
Sheryl Hays, Ann Arbor, MI (US);
Charles J. Stankovic, Saline, MI (US);
Kimberly S. Para, Ann Arbor, MI (US);
Michael K. Connolly, Ypsilanti, MI (US);
Paul Galatsis, Ann Arbor, MI (US);
William Harter, Chelsea, MI (US);
Aurash B. Shahripour, Ann Arbor, MI (US);
Mark Stephen Plummer, Dexter, MI (US);
Beth Lunney, San Diego, CA (US);
Bernd Janssen, Marlborough, MA (US);
Jay Bradford Fell, Longmont, CO (US);
James Knobelsdorf, Knoblesville, IN (US);
Sheryl Hays, Ann Arbor, MI (US);
Charles J. Stankovic, Saline, MI (US);
Kimberly S. Para, Ann Arbor, MI (US);
Michael K. Connolly, Ypsilanti, MI (US);
Paul Galatsis, Ann Arbor, MI (US);
William Harter, Chelsea, MI (US);
Aurash B. Shahripour, Ann Arbor, MI (US);
Mark Stephen Plummer, Dexter, MI (US);
Beth Lunney, San Diego, CA (US);
Bernd Janssen, Marlborough, MA (US);
Jay Bradford Fell, Longmont, CO (US);
Warner-Lambert Company, Morris Plains, NJ (US);
Abstract
The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family are described. In one embodiment, the compound is described by the generalized structure:and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis, using a compound of the invention or a pharmaceutical composition thereof, are described.